TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05930236

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lumbar medial branch block
Description: The lumbar medial branch block on three lumbar levels (L3-L4, L4-L5 and L5-S1) will be performed by ultrasound-guidance in a longitudinal plane and the correct placement of the needle will be verified by radiography to show if the two modalities are equivalent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocain
Description: Linisol infiltration with depomedrol and omnipaque

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: infiltration with linisol and omnipaque

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omnipaque
Description: infiltration with linisol and methylprednisolone
Study: NCT04826016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POL6326
Description: POL6326 (balixafortide): starting dose at 5.5 mg/Kg. Intravenous administration on day 1 and 8 of each 21-day cycle (+/- 1 day) (Phase Ib ARM A and Phase II ARM A ) or on day 1, 8 and 15 of each 28-day cycle (Phase Ib ARM B and Phase 2 ARM B) (+/- 1 day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POL6326
Description: POL6326 (balixafortide): starting dose at 5.5 mg/Kg. Intravenous administration on day 1 and 8 of each 21-day cycle (+/- 1 day) (Phase Ib ARM A and Phase II ARM A ) or on day 1, 8 and 15 of each 28-day cycle (Phase Ib ARM B and Phase 2 ARM B) (+/- 1 day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POL6326
Description: POL6326 (balixafortide): starting dose at 5.5 mg/Kg. Intravenous administration on day 1 and 8 of each 21-day cycle (+/- 1 day) (Phase Ib ARM A and Phase II ARM A ) or on day 1, 8 and 15 of each 28-day cycle (Phase Ib ARM B and Phase 2 ARM B) (+/- 1 day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POL6326
Description: POL6326 (balixafortide): starting dose at 5.5 mg/Kg. Intravenous administration on day 1 and 8 of each 21-day cycle (+/- 1 day) (Phase Ib ARM A and Phase II ARM A ) or on day 1, 8 and 15 of each 28-day cycle (Phase Ib ARM B and Phase 2 ARM B) (+/- 1 day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin: 1.23 mg/m2 (equivalent to 1.4 mg/m2 eribulin mesylate). Intravenous administration on day 1 and 8 of each 21-day cycle (+/- 1 day) (Phase Ib ARM A and Phase II ARM A ) or on day 1, 8 and 15 of each 28-day cycle (Phase Ib ARM B and Phase 2 ARM B) (+/- 1 day).
Study: NCT04624906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: 100 mg oral capsules twice daily for 1 year
Study: NCT04982276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Subjects will receive AK104 and AK109 in combination with paclitaxel.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK104
Description: Subjects will receive AK104 by intravenous administration.
Study: NCT01295073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trientine Hydrochloride
Description: Arm A's therapeutic intervention is the use of Trientine Hydrochloride for 10 days in the perioperative period.~All participating subjects will all receive cataract surgery according to present standards of care; however, subjects randomized the intervention group (trientine hydrochloride) will be on a 10 day course of oral Trientine at 1500mg administered for 7 days prior to and 3 days after surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: For Arm B there is no therapeutic intervention other than standard of care, which is cataract surgery.
Description: see above
Study: NCT04826016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin: 1.23 mg/m2 (equivalent to 1.4 mg/m2 eribulin mesylate). Intravenous administration on day 1 and 8 of each 21-day cycle (+/- 1 day) (Phase Ib ARM A and Phase II ARM A ) or on day 1, 8 and 15 of each 28-day cycle (Phase Ib ARM B and Phase 2 ARM B) (+/- 1 day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab-paclitaxel: 100 mg/m2. Intravenous administration on day 1 and 8 of each 21-day cycle (+/- 1 day) (Phase Ib ARM A and Phase II ARM A) or on day 1, 8 and 15 of each 28-day cycle (Phase Ib ARM B and Phase 2 ARM B) (+/- 1 day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab-paclitaxel: 100 mg/m2. Intravenous administration on day 1 and 8 of each 21-day cycle (+/- 1 day) (Phase Ib ARM A and Phase II ARM A) or on day 1, 8 and 15 of each 28-day cycle (Phase Ib ARM B and Phase 2 ARM B) (+/- 1 day).
Study: NCT04624906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 90 mg/m2 on days 1 and 2 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: day 1 of each cycle (375 mg/m2 intravenously for the first cycle and 1400 mg subcutaneously OR 375 mg/m2 intravenously for subsequent cycles (as per institutional procedures).
Study: NCT05606796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% Ophthalmic Solution
Description: 1 drop of 0.005% Latanoprost (preserved or preservative-free) would be instilled into the conjunctival sac daily for 12 weeks.
Study: NCT05357105

Intervention type: OTHER
Intervention: Numerical Pain Scales
Description: Patients who are about to receive regional nerve blocks will be administered a numerical pain scale (NRS) before, during and after the offset of the nerve block.
Study: NCT05912998

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cartilage regeneration technique
Description: autologous adipose tissue graft with hyaline cartilage graft mixed with fiberinglu

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: cartilage regeneration technique
Description: autologous adipose tissue graft with hyaline cartilage graft mixed with fiberinglu
Study: NCT06221085

Intervention type: DIAGNOSTIC_TEST
Intervention: Pain Pressure Threshold (PPT)
Description: Researchers measure pain pressure thresholds (PPTs) by applying a Pressure gauge algometer (PGA) over the myofascial trigger points (TrPs) on the body. PPT is defined as the lowest stimulus intensity at which a subject perceives pain.~The clinician applies it perpendicular to the long axis of the structure on which it is placed. The examiner increases the pressure at a rate of 1 kg/s until the subject feels pain or discomfort, and then the PPT values are measured three times for each muscle. Participants verbally report the first sensation of pain or discomfort, at which point the examiner stops the pressure.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pain Pressure Threshold (PPT)
Description: Researchers measure pain pressure thresholds (PPTs) by applying a Pressure gauge algometer (PGA) over the myofascial trigger points (TrPs) on the body. PPT is defined as the lowest stimulus intensity at which a subject perceives pain.~The clinician applies it perpendicular to the long axis of the structure on which it is placed. The examiner increases the pressure at a rate of 1 kg/s until the subject feels pain or discomfort, and then the PPT values are measured three times for each muscle. Participants verbally report the first sensation of pain or discomfort, at which point the examiner stops the pressure.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pain Pressure Threshold (PPT)
Description: Researchers measure pain pressure thresholds (PPTs) by applying a Pressure gauge algometer (PGA) over the myofascial trigger points (TrPs) on the body. PPT is defined as the lowest stimulus intensity at which a subject perceives pain.~The clinician applies it perpendicular to the long axis of the structure on which it is placed. The examiner increases the pressure at a rate of 1 kg/s until the subject feels pain or discomfort, and then the PPT values are measured three times for each muscle. Participants verbally report the first sensation of pain or discomfort, at which point the examiner stops the pressure.
Study: NCT05199285

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT06296602

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A prelevement for HPV genotyping and anal cytology will be carried out in addition to the anal swabs taken quarterly to screen for other sexually transmitted infections.
Description: A prelevement for HPV genotyping and anal cytology will be carried out in addition to the anal swabs taken quarterly to screen for other sexually transmitted infections. A questionnaire will be completed by the doctor to record the data of interest.
Study: NCT05751850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate
Description: HR070803 in combination with oxaliplatin, 5-fluorouracil, calcium folinate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel; gemcitabine
Description: nab-paclitaxel in combination with gemcitabine
Study: NCT05561192

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing exercises
Description: The initial proposal is for the first week to be adaptive, that is, learning to perform the exercises freely. During this period, students will be able to experience the activities and solve any doubts, as well as understand the process of a respiratory cycle, in which they will be initiated through a cycle of 12 times per minute. In the second and third weeks, the exercises will consist of 10 breathing cycles per minute (complete cycle consisting of 6 seconds, 2:2:2). It is important to note that each cycle contains the inspiration time, brief pause and expiration time in seconds. In the last week, each cycle will last 16 seconds, consisting of 4 seconds of inspiration, 4 seconds of pause and 8 seconds of expiration (4:4:8). Thus, the objective is to reduce the number of respiratory cycles per minute, as the intervention progresses.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory and strength exercise
Description: During the first two weeks, students will complete two laps of the circuit, with a 15-second break between one station and another and a 1-minute break between one lap and another. These first two weeks will focus on adaptation and technical learning of the exercises to be performed. From the third to the sixth week, one lap will be added to the circuit, totaling three laps, maintaining the aforementioned intervals. From week 7 to week 12, progressions will be carried out, reducing the interval time between one lap and another on the circuit to 30 seconds. For the purpose of controlling the intensity of the exercise, a subjective perception of effort scale will be used, composed of values from 1 to 10, the first being equivalent to very light effort activity, and ten, equivalent to maximum effort activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cooperative sports activities group
Description: Intervention with cooperative sports activities will be based on the pedagogical model for teaching sports called Cooperative Learning or Cooperative Learning. This pedagogical model has some predominant characteristics, such as student learning occurring with and through other students, through an approach that facilitates and enhances positive interdependence, where teachers and students act as co-learners. Thus, this teaching model encompasses two key points of cooperative learning: promoting interaction between students and interaction between students and teachers.~Also, in the planning of intervention classes with sports, the five points described as fundamental for learning to be considered cooperative will be considered. These are: face-to-face interaction, positive interdependence, individual responsibility, group processing, and social skills.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical education class
Description: The comparator group will take physical education classes normally, following the traditional menu in the discipline, without changes in the conduct of activities.
Study: NCT06148805

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pilates exercise and diaphragm manual technique
Description: pilates exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pilates exercise and diaphragm manual technique
Description: pilates exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pilates exercise and diaphragm manual technique
Description: pilates exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pilates exercise and diaphragm manual technique
Description: pilates exercises
Study: NCT05040360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT04777292

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use of a mobile health application until app completion
Description: Participants are asked to use esTOCma app approximately during 10 days, until app completion. This app has been designed to increase knowledge about obsessive-compulsive disorder (OCD), help seeking attitudes, and reduce stigmatizing attitudes. It consists in a game in which participants are asked to fight against the OCD stigma monster through ten missions. Participants have to liberate 10 characters who are prisoners of EsTOCma monster.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of a mobile health application until app completion
Description: Participants are asked to use esTOCma app approximately during 10 days, until app completion. This app has been designed to increase knowledge about obsessive-compulsive disorder (OCD), help seeking attitudes, and reduce stigmatizing attitudes. It consists in a game in which participants are asked to fight against the OCD stigma monster through ten missions. Participants have to liberate 10 characters who are prisoners of EsTOCma monster.
Study: NCT06002568

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Silent
Description: Apply wave file created in silence.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Binaural beats
Description: Apply wave file which is intended to generate binaural beats by applying waves of different frequency (1Hz difference) in each ear.
Study: NCT06191107

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Removable Partial Denture
Description: Integration of removable partial dentures made of PEEK for the treatment of tooth loss.
Study: NCT05755802

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PENG block
Description: A linear ultrasound probe will be placed longitudinally between the coracoid and the humeral head. After defining the humeral head, the tendon of the subscapular muscle and the deltoid muscle over it, the needle will be inserted using the in plane technique. When the needle will have passed through the deltoid muscle and touched the subscapularis tendon, a bone-like hard tissue will be felt and the needle could not be advanced further. The needle tip will be placed between the deltoid muscle and subscapularis tendon, and the injectate will be slowly administered.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder block
Description: The probe will be kept over the scapular spine to identify the trapezius and the supraspinatus muscle. Then, it Will be moved laterally to identify the concavity of the supraspinatus fossa and the hyper-echoic fascia of the supraspinatus muscle. In the concavity of the fossa, the suprascapular artery and the suprascapular nerve run in close proximity. A 50 mm nerve block needle will be used in the long axis view for the block. After confirming extravascular placement of the needle, injectate will be given below the supraspinatus fascia and then during axillary nerve block,The posterior surface of the humerus will be visualised in the short axis view. So, the circumflex artery will be visualised longitudinally. After confirming extra-vascular placement of the needle, injectate will be given into space.
Study: NCT05544149

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy
Description: Thoracic radiotherapy for ES-SCLC after first line immunecheckpoint inhibitors
Study: NCT05899582

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracranial-Intracranial Bypass Surgery
Description: Extracranial-intracranial bypass surgery plus medical treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical treatment alone
Description: Best medical treatment alone according to current clinical guidelines, including antiplatelet drugs (e.g. aspirin) and risk factor controls.
Study: NCT05018858

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloRx
Description: cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Study: NCT05293756

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OPTIMA-BP Intervention
Description: Participants will continue their regular medical care, supplemented by the OPTIMA-BP intervention:~1. Six weekly web-based education sessions on hypertension management.~2. Access to Medisafe, a medication management application (app) with a personalized medication adherence support (SMS reminder messages, adherence feedback, etc.) for 6 months.~3. Home Blood Pressure Monitoring (Omron series 10 home BP monitor). Participants will be asked to monitor and record their BP, 2x daily (AM and PM), twice a week, in a tracking log for 6 months.~4. Nurse Counseling Session with a research nurse for informal counseling, social support, and follow-up sessions regarding progress.~5. Optimizing HTN Treatment with 208 AA participants, in conjunction with their physician to maintain treatment goal BP: \< 130/80 mmHg. based on current HTN guidelines and study recommendations including chlorthalidone 12.5-25 mg/day or amlodipine 5-10 mg/day or as chosen by their doctor.
Study: NCT05912998

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cartilage regeneration technique
Description: autologous adipose tissue graft with hyaline cartilage graft mixed with fiberinglu
Study: NCT04299022

Intervention type: OTHER
Intervention: Vivigen Cellular Bone Matrix
Description: Allograft bone matrix
Study: NCT05178485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: FDA approved drug

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: FDA approved
Study: NCT05522595

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: S360
Description: In the first part of the intervention, after the CISS questionnaire completion by the patient, participant's eyes movements measurement will be performed using the reference procedure (standard of care).~A first diagnosis is established according to the interpretation of the results by a first evaluator.~In the second part of the intervention, the participant's eyes movements will be measured using the medical device S360.~A second diagnosis is established according to the interpretation of the software's displayed data by a second evaluator.
Study: NCT06543342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bystander Brief Motivational Intervention
Description: Group-based interactive intervention, conducted in two sessions, including multiple tasks and exercises to identify different levels of risk behavior, different types of strategies, and practicing responding to different scenarios. Personal goals for helping friends stay safe, and identifying whether intervention as a bystander was successful are included.
Study: NCT06304779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine group receive a loading dose of 1.5 mg/kg 2% lidocaine at anesthesia induction, followed by continuous intravenous infusion at 1.5 mg/kg/h until 24 hours postoperatively and Control group receive an equivalent volume of normal saline at anesthesia induction and throughout the perioperative period until 24 hours postoperatively.~Both groups will receive the same anesthesia and postoperative analgesia protocols, lung-protective ventilation strategy, and fluid, transfusion, and warming strategies. The only difference is the intervention during surgery, with the lidocaine group receiving continuous intravenous lidocaine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: atients receive an equivalent volume of normal saline at anesthesia induction and throughout the perioperative period until 24 hours postoperatively.
Study: NCT06432166

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2-hydroxybenzylamine acetate
Description: 2-hydroxybenzylamine acetate (2-HOBA) is taken three times per day for 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2-hydroxybenzylamine acetate
Description: 2-hydroxybenzylamine acetate (2-HOBA) is taken three times per day for 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2-hydroxybenzylamine acetate
Description: 2-hydroxybenzylamine acetate (2-HOBA) is taken three times per day for 16 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken three times per day for 16 weeks.
Study: NCT04994678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Training
Description: The Virtual reality based training group will receive a game based virtual reality training via XBOX 360or wii fit balance games. Player will be required to rapidly leaning away, squat to avoid overhead obstacles and try small jump to avoid lower obstacles, single leg stance, in addition person will required to do half squatting, side to side jumps and vertical jumps. Treatment will be provided 3 times a week or 6 weeks with each session lasting for 30-50 minutes. Progressively challenge will be increased.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Aerobic Exercise Training
Description: Moderate intensity continuous Aerobic exercises (Recombinant/Stationary cycling for 10-15 min with progression followed by treadmill walking for 10-15 min with progression, as well as stepping and Jogging). The session will be preceded by 5-7 minute warm-up \&amp; 7-10 min cool-down.
Study: NCT04379778

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Progressive moderate to high intensity aerobic exercise.